ImmuCell (NASDAQ:ICCC) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.15 and traded as low as $5.80. ImmuCell shares last traded at $5.82, with a volume of 45,363 shares changing hands.Wall Street Analyst Weigh InSeparately, Weiss Ratings reiterated a "sell (d+)" rating on shares of ImmuCell in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, ImmuCell presently has an average rating of "Sell".Check Out Our Latest Research Report on ICCCImmuCell Price PerformanceThe stock has a 50-day moving average of $5.72 and a two-hundred day moving average of $6.15. The firm has a market cap of $52.67 million, a price-to-earnings ratio of 22.39 and a beta of 0.20. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The company had revenue of $5.51 million for the quarter. Hedge Funds Weigh In On ImmuCellA hedge fund recently raised its stake in ImmuCell stock. Geode Capital Management LLC raised its position in shares of ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,852 shares of the biotechnology company's stock after purchasing an additional 2,907 shares during the quarter. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors. About ImmuCell (Get Free Report)ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics. The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.Featured ArticlesFive stocks we like better than ImmuCellThe boring AI play that could pay up to $4,290 monthlyTrump’s “real estate deal for America” explainedPut $1,000 into this stock by Jan 1 [Not NVDA]ALERT: Drop these 5 stocks before January 2026!Trump Did WHAT??This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in ImmuCell Right Now?Before you consider ImmuCell, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here